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Lise Willems,1 Rapha€el Porcher,2,5,6 Matthieu Lafaurie,3 Isabelle Casin,4 Marie Robin,1
Alienor Xhaard,1 Anna Lisa Andreoli,1 Paula Rodriguez-Otero,1 Nathalie Dhedin,1
Gerard Socie,1,5,6 Patricia Ribaud,1,5,6 Regis Peffault de Latour1,6Clostridium difficile (C. difficile) infection was observed in 13% of recipients after hematopoietic stem cell
transplantation (HSCT), mainly in the first month posttransplantation. Risk factors were cord blood as the
source of stem cells, acute graft-versus-host disease (GVHD), and total body irradiation (TBI). No association
was found with an increased risk of mortality. The purpose of this study was to evaluate the incidence, risk
factors, and outcome of C. difficile infection (CDI) after HSCT. We conducted a single-center, retrospective,
cohort study on all patients who received an allogeneic HSCT from January 2004 to December 2007. All
patients with diarrhea in the first year after HSCTwere tested for the presence of C. difficile in stools. Among
the 407 assessable patients, 53 presented at least 1 CDI in the first year post-HSCT. The total incidence
rate was 5.6 cases of CDI per 10,000 patient-days. Fifty percent of cases were diagnosed in the first month
after HSCT, and 95% occurred during the first 6 months. Fewer than 5% of patients with CDI had severe
diarrhea and severe complications were never observed. TBI in the conditioning regimen, cord blood as
the source of stem cells, and acute graft-versus-host disease (aGVHD) were independently associated with
CDI. Six patients (11%) had a recurrence of CDI. Four patients required second-line treatment with vanco-
mycin. With a median follow-up of 22 months, the 2-year overall survival rates were similar between patients
who presented a CDI and those who did not. CDI was observed in approximately 13% of recipients after
HSCT, mainly in the first month posttransplantation and was associated with CB, aGVHD, and TBI. CDI
was not associated either with severe complications or with an increased risk of mortality in this large cohort
of patients.
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Clostridiumdifficile (C. difficile) is an anaerobic, gram-
positive bacillus, responsible for 20% of antibiotic-
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6/j.bbmt.2012.02.010various clinical presentations from mild diarrhea to
life-threatening toxic megacolon, colon perforation,
and death [1]. The rates of colonization are usually
only 2% to 3% for healthy adults and increase to 20%
to 30% among hospitalized patients [2]. Diagnosis of
C. difficile infection (CDI) requires identification of
a toxin-producing C. difficile strain in patients’ stools.
A 2-step protocol, first using an enzyme-linked immu-
noassay (EIA) for glutamate dehydrogenase (GDH) an-
tigen and for toxins A and B followed by toxigenic stool
culture if GDH is positive, has a high sensitivity [3,4].
The major risk factors for CDI are hospitalization,
old age (ie,$65 years), and exposure to antibiotics [5].
In the general population, the cumulative attributable
mortality to CDI at 30 days ranges from 0.9% to
16.7%, with greater morbidity and mortality in recent
years [6-10]. Increasing incidence associated with the
emergence of more virulent strains since 2002 raises
new concerns regarding the impact on mortality,
especially in immunocompromised patients [10].1295
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(HSCT), patients are exposed to several well-
recognized risk factors for the development of CDI,
including broad-spectrum antibiotic exposure, length
of hospitalization, altered integrity of the intestinal mu-
cosa [11], and immunodeficiency [12,13]. Furthermore,
the use of allogeneic HSCT has expanded progressively
to older patients due to the development of reduced-
intensity conditioning regimens [14]. However, until
now, CDI after HSCT has been reported in a small
number of studies. CDI accounts for 4% to 20.4% of
the episodes of diarrhea in HSCT recipients [15].
The rate of CDI relapse after correctly administered
treatment, the frequency of complications, as well as
the rate of mortality remains unknown in this setting.
Only 1 study found an association between CDI and
acute graft-versus-host disease (aGVHD) as well as
an increase in mortality of the patients who developed
CDI after allogeneic HSCT [16].
The purpose of this retrospective, single-center
study was to determine the incidence, risk factors,
and prognostic significance of CDI after HSCT.PATIENTS AND METHODS
Population Study
A retrospective review of all patients who under-
went allogeneic HSCT at Saint-Louis Hospital
(Paris, France) between January 1, 2004, and Decem-
ber 31, 2007, was undertaken using database and
medical records. All patients with diarrhea after the
beginning of the conditioning regimen and during
the first posttransplantation year were tested for the
presence of C. difficile in stools. Patients’ stools were
also systematically tested for other bacterial, fungal,
and viral pathogens. C. difficile was first detected in
stools by EIA for C. difficile glutamate dehydrogenase
(Wampole C Diff quick check, TechLab, Black-
sburg,VA). If the results were positive, EIA for toxins
A and B in stools (Wampole ToxA/B check, Tech-
Lab, Blacksburg, VA) and toxin EIA on C. difficile
colonies after culture were performed to determine
the presence of a toxin-producing C. difficile strain.
Positive results were reported if GDH and EIA toxins
or toxigenic culture were positive. Only primary
episodes of CDI were included.HSCT Procedures
All patients were hospitalized in private rooms.
Antimicrobial prophylaxis consisted of amoxicillin
from the beginning of the conditioning regimen (until
fever called for intravenous antibiotics) plus ofloxacin
in cases of neutropenia-inducing conditioning regi-
men. Oral acyclovir and fluconazole were started at
the onset of the conditioning regimen. Fluconazolewas discontinued if the patient required treatment
with any other systemic antifungal agent. Prophylactic
trimethoprim/sulfamethoxazole was given after
engraftment. First-line intravenous empiric therapy
usually included a broad-spectrum beta-lactam.CDI Definition
CDI was defined according to the European Soci-
ety of Clinical Microbiology and Infectious Diseases
[17]. Briefly, CDI diagnosis required diarrhea (semi-
liquid or liquid stool twice or more in 24 hours) with-
out evidence of another cause and a stool test result
for the presence of toxigenic C. difficile. The severity
of gastrointestinal symptoms was graded according
to the National Cancer Institute Common Terminol-
ogy Criteria for Adverse Events [18]. Severe CDI was
defined by admission to an intensive care unit for
complications, colectomy, and/or death related to
CDI. Recurrence was a new episode of diarrhea and
a positive toxin assay within 8 weeks after a first
correctly treated episode. CDI treatment failure was
defined by an increase in stool frequency as reported
by the patient, lack of improvement in stool consis-
tency after 3 days, or new signs of severe colitis
[17]. GVHD was defined and graded according to
standard criteria [19].Statistical Analysis
We first analyzed the incidence and risk factors of
CDI in the first year after HSCT. Incidence rates
(ie, average hazards) over post-HSCT time periods
were estimated using standard methodology and
graphically illustrated by a cumulative hazard curve.
Risk factors were analyzed using univariable and mul-
tivariable Cox proportional hazard cause-specific
models, in which transplantation characteristics
were time-fixed covariates and clinical parameters in
the posttransplantation period time-dependent cova-
riates. The proportional hazards assumption was
checked by examination of Schoenfeld’s residuals
and Grambsch and Therneau’s lack-of-fit test. Be-
cause hazards were not found to be proportional,
time-varying effects were used in the models by sep-
arating early and late effects with a cutoff arbitrarily
defined according to the shape of the cumulative
hazard of CDI. The association between CDI (either
at the time of HSCT or thereafter) and the outcome
was also analyzed. Survival probabilities were then
estimated by the Kaplan-Meier estimator and analy-
ses performed using proportional hazard or propor-
tional cause-specific hazard models. All tests were
2-sided and P values #.05 were considered as indi-
cating significant association. All analyses were
performed using the R statistical software version
2.10.1 (R Development Core Team, Vienna, Austria).
Table 1. Characteristics of Patients with orwithout CDI after
HSCT
Variables No CDI (n 5 354) CDI (n 5 53)
Male gender, no. (%) 214 (60.5) 35 (66)
Median age years (range) 32 (4-68) 26 (4-59)
Underlying disease, no. (%)
Acute leukemia 165 (46.6) 28 (52.8)
Myelodysplastic/myeloproliferative 42 (11.9) 6 (11.3)
Chronic leukemia 25 (7.1) 4 (7.5)
Lymphoma 37 (10.5) 6 (11.3)
Plasma cell disorder 20 (5.6) 1 (1.9)
Aplastic anemia 40 (11.3) 5 (9.4)
Hemoglobinopathy 23 (6.5) 3 (5.7)
Inherited disorder 2 (0.6) 0 (0)
Malignant disease, no. (%) 289 (81.6) 45 (84.9)
RIC regimen, no. (%)* 147/352 (41.8) 17/51 (33.3)
TBI $12 Gy, no. (%) 65/343 (19) 17 (32.1)
Source of stem cells, no. (%)
Bone marrow 146 (41.2) 20 (37.7)
Peripheral blood stem cell 159 (44.9) 21 (39.6)
Cord blood 49 (13.8) 12 (22.6)
Matched related donor, no. (%) 182/351 (51.9) 22 (41.5)
Male donor, no. (%) 165/318 (51.9) 30/45 (66.7)
Positive CMV serology, patient, no. (%) 205/333 (61.6) 27/50 (54)
Positive CMV serology, donor, no. (%) 172/333 (51.7) 17/51 (33.3)
GVHD prophylaxis
Cyclosporine, no. (%) 332 (93.8) 52 (98.1)
Methotrexate, no. (%) 175 (49.4) 31 (58.5)
Cellcept, no. (%) 101 (28.5) 10 (18.9)
CDI indicates Clostridium difficile infection; HSCT, hematopoietic stem
cell transplantation; RIC, reduced intensity conditioning; TBI, total
body irradiation; Gy, Gray; CMV, cytomegalovirus; GVHD, graft-
versus-host disease.
*Reduced intensity conditioning regimen excluded all conditioning reg-
imens with either irradiation >10 Gy or busulfan $16 mg/kg or cyclo-
phosphamide $150 mg/kg/day.
Table 2. Risk Factors for CDI including Gut GVHD Taking
into Account the Variation of Influence of TBI and aGVHD
with Time
Variables HR (95% CI) P value
TBI $12 Gy
CDI 0-2 months post-HSCT 2.3 (1.2-4.5) .01
CDI >2 months post-HSCT 0.6 (0.1-2.5) .50
aGVHD grade $2
CDI 0-2 months post-HSCT 1.4 (0.6-3.4) .50
CDI >2 months post-HSCT 7.5 (1.7-34.3) .01
Acute gut GVHD $2
CDI 0-2 months post-HSCT 1.8 (0.7-4.6) .20
CDI >2 months post-HSCT 27.2 (3.5-210.4) .002
Cord blood 2 (1-3.8) .04
CDI indicates Clostridium difficile infection; GVHD, graft-versus-host dis-
ease; TBI, total body irradiation; aGVHD, acute graft-versus-host dis-
ease; HR, hazard ratio; CI, confidence interval; Gy, Gray; HSCT,
hematopoietic stem cell transplantation.
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Patients Characteristics
During the study period (2004-2007), 414 patients
received an allogeneic HSCT. Grading for aGVHD
was not available for 6 of them, and 1 other patient
was excluded from the analysis because of a late C. dif-
ficile infection occurring more than 500 days after
transplantation. Clinical characteristics of the 407 re-
maining patients (249 men, 61.2%) are detailed in
Table 1. Clinical data were similar between patients
who presented a CDI and patients who did not, except
for the use of total body irradiation (TBI; 32.1% and
19%, respectively) and cord blood as the source of
stem cells (22.6% and 13.8%, respectively) as illus-
trated in Table 2.Figure 1. Cumulative hazard of Clostridium difficile infection (CDI) after
hematopoietic stem cell transplantation (HSCT). The black curve repre-
sents the non-parametric estimate of the cumulative hazard of CDI after
HSCT, and the grey curve represents the estimate obtained assuming
piecewise constant hazards on 3 separate periods. Incidence was 61
of 10,000 patient-days during the first week after HSCT, 12 of 10,000
patient-days from week 1 to week 8, and 1.6 of 10,000 patient-days
from week 8 to week 52 after HSCT.CDI Incidence
Of the 407 patients, 53 (13%) developed a CDI.
The mean incidence during the first year after
HSCT was 5 per 10,000 patient-days. This incidence
varied according to the delay after the HSCT proce-
dure with a peak incidence of 61 per 10,000 patient-
days during the first week immediately after HSCT.
At this point, the incidence decreased progressivelyuntil 1.6 per 10,000 patient-days 2 months after
HSCT (Figure 1). The 1-year cumulative incidence
was 13%. Nevertheless, 50% of CDI occurred during
the first month and 95% during the first 6months after
HSCT. The median time to develop CDI was 25 days
after HSCT (range from 3 days before transplantation
to 276 days after transplantation).We also observed an
increase of CDI incidence during the study period with
more cases in 2006 to 2007 compared with 2004 to
2005, although these results were not significantly
different (hazard ratio [HR] 5 1.26 and 1.79, respec-
tively, overall P 5 .068). The new emergent epidemic
strain ribotype 27 was not isolated in our cohort, and
all cases resulted from the classic strain of C. difficile.
Table 3. Characteristics of Patients with CDI after HSCT
CDI (n 5 53) Not Available
Median number of antibiotics used
in the previous 4 weeks (range)
4 (1-7) -
Neutropenia (WBC count <500), no. (%) 24 (45) -
Albumin level #2.5 mg/dL, no. (%) 3 (7) 7
Proton pump inhibitor 53 (100) -
Clinical symptoms
Fever, no. (%) 20 (39) 2
Diarrhea
WHO 3-4, no. (%) 47 (96) 4
WHO 1-2, no. (%) 2 (4) 4
Abdominal cramps, no. (%) 12 (25) 5
Concomitant infections, no. (%) 25 (48) 1
CDI indicates Clostridium difficile infection; HSCT, hematopoietic stem
cell transplantation; WBC, white blood cell; WHO, World Health
Organization.
None of the patients had a creatinine level >2.5mg/dL, and bloody stools
were never present.
WHO 1-2: increase of 2 to 6 stools per day or nocturnal stools or mod-
erate cramping.
WHO 3-4: increase of $7 stools per day or incontinence or severe
cramping or grossly bloody diarrhea or need for parenteral support.
For 4 patients who had diarrhea, WHO grading was not available.
Figure 2. Overall survival of patients with or without Clostridium diffi-
cile infection (CDI) after hematopoietic stem cell transplantation
(HSCT). Patients with CDI are represented in the gray line (n 5 53),
whereas others are represented in the black line (n 5 354).
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tation unit was reported during the study period.Risk Factors for CDI
Clinical and biological characteristics of patients
who developed CDI are described in Table 3. A sys-
tematic concomitant test for other pathogens allowed
other causes of infectious diarrhea to be excluded,
although concomitant infections were frequently iden-
tified on blood samples (25 patients), including mostly
viral infections (7 cytomegalovirus [CMV], 2 herpes
simplex virus, 1 adenovirus, and 12 others) or bacterial
infections (5 cocci gram-positive and 3 bacille gram-
negative bacteremia, and 2 others). Four patients were
diagnosed with concomitant invasive aspergillosis.
For the risk factor analysis, variables are men-
tioned in Table 1. Any case of aGVHD was analyzed
as a time-dependant covariable, and only aGVHD
that had occurred before CDI was considered for the
CDI group.Multivariate analysis identified the follow-
ing risk factors for CDI: cord blood as the source of
stem cells, TBI $12 Gy, and aGVHD grade 2 or
more. The effect of TBI and aGVHD on the hazard
of CDI were not found to be constant with time
(P 5 .01). A model with separate effects on early
CDI (ie, CDI occurring in the first 2 months after
HSCT) and late CDI (CDI occurring more than 2
months after HCST) is shown in Table 2. A separate
model including gut aGVHD instead of grade 2 or
more aGVHD (Table 2) shows that gut aGVHD is
strongly associated with the occurrence of late CDI.
Notably, CDI was not found to be significantly
associated with the risk of occurrence of a subsequent
grade 2 or more aGVHD (HR, 1.24; 95% confidenceinterval [CI], 0.72-2.15; P 5 .43) or gut GVHD (HR,
1.23; 95% CI, 0.67-2.28; P 5 .51).
CDI Treatment and Outcome
All patients except 5 received oral metronidazole as
the first-line treatment with a median treatment length
of 15 days (range, 4-55 days) for each episode. Other
patients (n 5 5) received intravenous metronidazole
when the oral route was not feasible. Five patients
(2.6%) experienced a recurrence of CDI, 2 of them
having more than 1 recurrence. Five patients required
treatment with oral vancomycin as the second-line
treatment, replacing metronidazole. Reasons for van-
comycin use were heterogeneous including multiple
recurrences (1 patient), persistent diarrhea combined
with Crohn disease (1 patient), persistent toxin excre-
tion after metronidazole treatment (1 patient), and
also incomplete data (2 patients). Nevertheless, medi-
cal or surgical complications were never observed and
every patient responded to medical treatment. No
severe CDI was observed in our cohort. Thirty-day
mortality arising from CDI was zero. With a median
follow-up of 29 months, we did not observe any differ-
ence in the mortality rates between both groups of
patients, with or without CDI (Figure 2).DISCUSSION
Little has been published about the incidence of
CDI posttransplantation and most of the available
data concern autologous HSCT [15] and solid-organ
transplantation [20]. In this setting, the rate of inci-
dence ranges from 3% to 15% [21-25]. However, in
most studies, the incidence was only estimated among
Biol Blood Marrow Transplant 18:1295-1301, 2012 1299Clostridium difficile and Transplantationpatients who had developed diarrhea and may not
reflect the real incidence in patients who underwent
transplantation. Our retrospective study represents
the largest study to date conducted in patients after
HSCT. Our findings indicate a cumulative incidence
of 13% at 1 year, with 50% of infections occurring
during the first month after HSCT. Similar or higher
rates (13% and 18%) have previously been reported
in studies of 75 and 216 allo-HSCT recipients, respec-
tively [16,26]. Another study found an incidence of
almost 30% among 26 allo-HSCT recipients [27].
The peak incidence observed during the first week
posttransplantation may be partly explained by colonic
mucosal damage resulting from the conditioning regi-
men. This is illustrated in our study by the association
betweenTBI and a higher risk of CDI in the early post-
transplantation period. Furthermore, CDI does not
only result from the acquisition of toxigenic strains of
C. difficile but also requires alteration of the digestive
tract, arising from the conditioning regimen (including
TBI) and from gut GVHD in allo-HSCT recipients.
Clinical expression of CDI is highly variable, and the
immunocompromised status of our patients limits the
value and the specificity of clinical symptoms. Co-
infections were frequent, as already reported in this
setting [16], and in some cases may have caused fever,
abdominal pain, or diarrhea. Diarrhea from gut
GVHD with concomitant C. difficile toxin detection
may have led to an overestimation of the rate of CDI.
Only a prospective study would remove this bias. Al-
though the 2-step detection on C. difficile used in our
study has a high sensitivity, a recent study has shown
that the performance of antigen-based methods varies
with the genotype of C. difficile, contrary to molecular
methods [28]. Nucleic acid amplification tests are
generally more sensitive than toxin EIA and could
therefore limit false-negative results [29].
In multivariate analysis, not only TBI but also
aGVHD and the use of cord blood as the source of
stem cells were identified as risk factors for CDI.
Chakrabarti et al. [16] also found aGVHD grade 3 to
4 to be a risk factor for CDI, but our study is the first
to report the use of cord blood as a risk factor. This
probably stems from higher immunodeficiency and
longer engraftment periods leading to longer hospital-
ization and exposure to antibiotics [30]. GVHD and
cord blood transplantations delay the immune recon-
stitution and are a precursor to other infections like
CMV [31] or invasive aspergillosis [32], leading again
to prolonged hospitalization and exposure to antibi-
otics. Inability to produce toxin-neutralizing anti-
bodies is associated with a higher risk of developing
an active infection in colonized patients [33] and may
theoretically result from GVHD and its treatment.
Furthermore, gut GVHD may increase the direct ef-
fects of C. difficile toxins on enterocytes by alteringthe integrity of the intestinal mucosa, as illustrated
by an approximately 30-fold increased risk of CDI in
patients with gut GVHD in our study.
Conversely, in a case-control study of 37 allogeneic
HSCT recipients withCDI,Dubberke et al. [34] found
an increased risk of GVHD, severe GVHD, and gut
GVHD after CDI, contrary to our findings. The
high rate of severe CDI (57%) in their cohort may pro-
vide at least a partial explanation of this disparity. The
difficulties in identifying other known risk factors, such
as exposure to antibiotics or the use of proton pump
inhibitors [35,36], are probably due to the ubiquity of
these traditional risk factors among HSCT recipients.
All our patients with CDI had received at least 1 of
the 3 most commonly administered antibiotic families,
including third-generation cephalosporin, broad-
spectrum penicillin, and quinolone [2,5], during the
month preceding CDI. Another study has shown that
diabetes mellitus, administration of a third or fourth-
generation cephalosporin, and being in the pre-
engraftment phase are risk factors for CDI after
allogeneic HSCT [34].
Several studies have compared metronidazole fa-
vorably over vancomycin as an effective treatment
for CDI [37,38], and metronidazole may reasonably
be proposed to patients with nonsevere CDI on the
basis of cost and concerns to limit vancomycin-
resistant enterococcus selection provided by oral van-
comycin [17,39]. In our study, all patients received
oral metronidazole as a first-line treatment, which
was efficacious in all cases. The reported recurrence
rate ranges from 5% to 66%, with a mean of 20% af-
ter therapy with either vancomycin or metronidazole
[40]. Our findings indicate a recurrence rate of only
9.4%, despite persisting exposure to additional anti-
biotics for treatment or prophylaxis of other infec-
tions, with no associated complications. Notably, we
did not observe either severe CDI or death attribut-
able to CDI, contrary to both previous studies of
allo-HSCT recipients [16,34]. In the first study of
37 patients, the increased risk of death was
evaluated at 180 days and restricted to patients with
severe CDI (57% of patients) [34]. The other study
dealt with 75 patients who underwent HSCT be-
tween 1994 and 1999. Seven of 10 patients who devel-
oped CDI died from GVHD or infections, compared
with 19 of 65 patients in the noninfected group. Bet-
ter outcome and reduced mortality resulting from ad-
vances in the daily care of patients undergoing HSCT
over the last decade make it difficult to make compar-
isons between these results [41]. CDI-related mortal-
ity may also depend on the virulence of the
predominant strain and, as such, further prospective
studies should be able to confirm our findings. Never-
theless, several prophylactic infectious procedures
must be respected to avoid the spread of CDI,
1300 Biol Blood Marrow Transplant 18:1295-1301, 2012L. Willems et al.including patient isolation, enhanced environment
cleaning with chlorine-based agents, appropriate pro-
tective clothing, and strict hand hygiene [42].
In conclusion, CDI is observed in approximately
13% of recipients after HSCT, mainly in the first
month post-HSCT. Risk factors for CDI are TBI,
cord blood as the source of stem cells, and prior
aGVHD. Contrary to previously published data, the
outcome was favorable upon administration of appro-
priate treatment in this particular population.ACKNOWLEDGMENTS
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